Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 46 min ago
Peer-reviewedCC BY 4.0Respirology (Carlton, Vic.)

Asthma: From Phenotypes to Endotypes—Beyond Type 2 Inflammation

  • Mario Fernando1,2
  • Gregory G. King1,2,3
  1. 1Department of Respiratory and Sleep Medicine Royal North Shore Hospital St Leonards New South Wales Australia
  2. 2Northern Clinical School, Faculty of Health and Medicine, University of Sydney Camperdown Australia
  3. 3The Woolcock Institute of Medical Research, Macquarie University Macquarie Park Australia
Read full textPDFDOICite

Abstract

Asthma is a heterogeneous syndrome featuring variable pathophysiology, clinical presentation and treatment response. This review examines a comprehensive endotype‐phenotype framework for asthma assessment with an emphasis on characteristics beyond T2 inflammatory status alone. Endo‐phenotype assessment can be performed across three domains: clinical (symptoms, exacerbations, co‐morbidities), structural and physiological, and inflammatory endotype. The clinical domain includes mucus hypersecretion, perception of airway narrowing, and obesity‐related asthma. Airway remodelling is the central, structural endo‐phenotype that defines asthma, given its relationship with fixed airflow limitation, airway hyperresponsiveness, small airway dysfunction, lung function decline, and asthma severity. However, it is the most difficult parameter to measure, and it is increasingly recognised that there is a critical need to be able to measure it longitudinally, beyond bronchial biopsy. Finally, T2‐high asthma is relatively well characterised with several effective anti‐inflammatory therapies available, including a range of biologics. In contrast, T2‐low asthma remains a heterogenous and potentially difficult to characterise endo‐phenotype, although some treatment studies have demonstrated benefit when subjects have been appropriately characterised and selected. Emerging multi‐omic approaches may enhance the detailed characterisation of patients in future. Adopting an endo‐phenotype framework allows clinicians and researchers to confront the complexity of asthma, better manage patients with a precision medicine approach and enhance mechanistic understanding, which is critical for new therapeutics to be developed for asthma.

Related

  1. Airway epithelial cell–lung macrophage crosstalk in type 2-high and low asthma endotypes: mechanisms and therapeutic strategies
    Yinuo Wang, Yuxuan Sun, Suning Mu +3
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textPhysiologyCrossrefPMC
  2. Zileuton Beyond Asthma: A Multifaceted 5-Lipoxygenase Inhibitor With Emerging Therapeutic Potential Across Inflammation, Cancer, Neuroprotection, and Fibrosis
    Victor D Ivancev, Joshua Iskander, Julia Hanna +3
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Chimeric antigen receptor-engineered cell therapy for asthma: advances in targeting type 2 inflammation and translational challenges
    Yifei Niu, Chenyang Jian, Peize Liu +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  4. Association of airway CCL28 with type 2 inflammation and secretory IgA in patients with asthma
    Xiaohan Jiang, Jinmei Zhang, Ke Xu +5
    PLOS OnePeer-reviewedCC BYFull textGeneral biochemistryCell biologyPLOSEurope PMCPMC
  5. Pathogen-associated heterogeneity in pulmonary sepsis: from inflammatory phenotypes and transcriptomic endotypes to precision medicine
    Chun Wang, Cheng Xi, Ying Zhang +6
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{fernando2026asthma,
  title = {{Asthma: From Phenotypes to Endotypes—Beyond Type 2 Inflammation}},
  author = {Mario Fernando and Gregory G. King},
  journal = {Respirology (Carlton, Vic.)},
  year = {2026},
  month = oct,
  doi = {10.1002/resp.70322},
  url = {https://doi.org/10.1002/resp.70322},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Asthma: From Phenotypes to Endotypes—Beyond Type 2 Inflammation
AU  - Mario Fernando
AU  - Gregory G. King
PY  - 2026
DA  - 2026/10/07
JO  - Respirology (Carlton, Vic.)
DO  - 10.1002/resp.70322
UR  - https://doi.org/10.1002/resp.70322
AB  - Asthma is a heterogeneous syndrome featuring variable pathophysiology, clinical presentation and treatment response. This review examines a comprehensive endotype‐phenotype framework for asthma assessment with an emphasis on characteristics beyond T2 inflammatory status alone. Endo‐phenotype assessment can be performed across three domains: clinical (symptoms, exacerbations, co‐morbidities), structural and physiological, and inflammatory endotype. The clinical domain includes mucus hypersecretion, perception of airway narrowing, and obesity‐related asthma. Airway remodelling is the central, structural endo‐phenotype that defines asthma, given its relationship with fixed airflow limitation, airway hyperresponsiveness, small airway dysfunction, lung function decline, and asthma severity. However, it is the most difficult parameter to measure, and it is increasingly recognised that there is a critical need to be able to measure it longitudinally, beyond bronchial biopsy. Finally, T2‐high asthma is relatively well characterised with several effective anti‐inflammatory therapies available, including a range of biologics. In contrast, T2‐low asthma remains a heterogenous and potentially difficult to characterise endo‐phenotype, although some treatment studies have demonstrated benefit when subjects have been appropriately characterised and selected. Emerging multi‐omic approaches may enhance the detailed characterisation of patients in future. Adopting an endo‐phenotype framework allows clinicians and researchers to confront the complexity of asthma, better manage patients with a precision medicine approach and enhance mechanistic understanding, which is critical for new therapeutics to be developed for asthma.
SN  - 1323-7799
SN  - 1440-1843
ER  -